The stock is still down more than 20% from the start of the year through yesterday’s close, taking a massive hit after its botched rollout of a copycat Wegovy pill.
Hims jumps after RFK Jr. announces FDA may loosen regulations for 12 peptides
The stock is still down more than 20% from the start of the year through yesterday’s close, taking a massive hit after its botched rollout of a copycat Wegovy pill.